Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovate Biotechnology CoROCO:4130 -4.62%72 EBITDA Margin % is 3.18% as of Dec. 2025, which is 79% below its 10-year median of 14.85. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Genovate Biotechnology Co ranks better than 75.29% on this metric.
Genovate Biotechnology Co (ROCO:4130) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genovate Biotechnology Co EBITDA Margin % Related Terms
Genovate Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4130 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co (ROCO:4130) has a EBITDA Margin % of 3.18% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genovate Biotechnology Co and its competitors. This is 79% below median its historical median of 14.85. Over the past decade, Genovate Biotechnology Co's EBITDA Margin % has ranged from 6.24 to 48.24. According to the industry distribution chart, Genovate Biotechnology Co ranks #232 out of 939 companies in the Biotechnology industry, placing it in the top 24.7%.
Is Genovate Biotechnology Co's EBITDA Margin % too high?
Genovate Biotechnology Co's current EBITDA Margin % of 3.18% is 79% below median its 10-year median of 14.85. Over the past 10 years, this metric has ranged from a low of 6.24 to a high of 48.24. Based on the distribution chart, Genovate Biotechnology Co ranks #232 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #232 out of 939 companies for EBITDA Margin %. This places Genovate Biotechnology Co in the top 25% of its industry — outperforming the majority of peers. Historically, Genovate Biotechnology Co's own EBITDA Margin % has ranged from 6.24 to 48.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current EBITDA Margin % is 3.18%, which is 79% below median its own 10-year median of 14.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current EBITDA Margin % is 3.18%, which is 79% below median its 10-year median of 14.85. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current EBITDA Margin % is 3.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
EBITDA Margin %: 3.18% (79% below median its 10-year median of 14.85)
GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score
Get the complete analysis for ROCO:4130
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
